Public research overviewHow we research Research team
Clinical Trial Equipment & Ancillary Solutions: the commercial landscape
Clinical Trial Equipment & Ancillary Solutions connects pharmaceutical sponsors and contract research organizations with the equipment, non-drug supplies and support needed by investigator sites and trial participants. Public portfolios cover laboratory and clinical equipment, monitoring devices, wearables, site consumables and patient kits. These categories are distinct from the investigational medicine itself.
The offering is more than equipment distribution. Woodley Trial Solutions markets rental and purchasing alongside kits, digital health devices and support services. Resonant Clinical Solutions offers rental, direct purchase and asset management, with delivery, calibration, continuing support and recovery. Ancillare positions ancillary sourcing and supply-chain management as a dedicated service. Equipment manufacturers, specialist integrators and logistics partners consequently perform different business roles, even when a sponsor contracts through one provider.
The purchasing decision is about availability and accountability as well as ownership. Sponsors and CROs need equipment and supplies aligned with site requirements, while sites need continuity and accessible support. Durable-equipment rental, purchased assets, consumable replenishment and service fees should therefore remain distinguishable in commercial comparisons. A marketed global service does not establish that every device is authorized, stocked or available in every destination.
Sources and supporting claims 3
- The Future of Clinical Trial Supply Chain is Now (opens in a new tab)ancillare.com
- Ancillare identifies laboratory equipment, medical devices, monitoring devices, wearables, clinical-site consumables and patient kits as non-investigational, non-drug ancillary categories.
- Clinical Trial equipment supplier & rental | Woodley Trial Solutions (opens in a new tab)woodleytrialsolutions.com
- Woodley markets equipment rental and purchasing, patient kits, digital health devices, logistics, calibration and technical support to pharmaceutical, biotechnology and CRO customers.
- Clinical Trial Ancillary Equipment Sourcing, Delivery & Recovery (opens in a new tab)resonantclinical.com
- Resonant offers clinical-trial equipment procurement, delivery, calibration, continuing support and recovery, with rental, direct-purchase and asset-management options.
360iResearch introduction
Inside the research
Coverage at a glance
Selected branches from the published table of contents. Follow a chapter to see every subchapter in context.
Chapter 7 Region
- Asia-Pacific
- North America
- Latin America
- Europe
Chapter 8 Group
- ASEAN
- GCC
- European Union
- BRICS
Chapter 9 Country
- United States
- Canada
- Mexico
- Brazil
Capital investment and partnerships reshape equipment competition
Specialist platforms have changed ownership and expanded their scope. On October 18, 2024, Audax announced completion of its acquisition of Avantor's clinical-services business and its rebranding as Resonant Clinical Solutions, bringing together MESM, Therapak and EPL Archives. For equipment buyers, this changed the ownership context of established brands; it did not by itself demonstrate improved delivery performance or altered contract terms.
On January 14, 2026, Sagard NewGen announced a minority investment in Quipment alongside its founders and management. The stated objective was growth and international expansion, not a takeover. This introduces expansion capital into equipment solutions, while the conversion of that ambition into additional country-level capabilities remains a separate commercial question.
On September 30, 2026, Resonant announced that it had acquired Germany-based Labfish and its United States and United Kingdom affiliates. The disclosed combination adds rental equipment, calibration, kitting and import/export-related capabilities. The supported competitive effect is a broader offering under one owner; integration benefits and customer outcomes were not established.
Supplier differentiation also extends to manufacturer partnerships. On October 7, 2026, Resonant and Haier Biomedical announced the launch of a natural-refrigerant benchtop centrifuge through an exclusive partnership. This illustrates differentiation beyond equipment aggregation. It establishes a launch, not universal country availability, purchasing uptake or an industry-wide replacement cycle.
Sources and supporting claims 4
- Audax Private Equity Completes Carveout of Avantor, Inc.’s Clinical Services Business and Rebrands the Company as Resonant Clinical Solutions (opens in a new tab)nasdaq.com
- Audax's October 18, 2024 announcement states that it completed the acquisition of Avantor's clinical-services business and rebranded it Resonant Clinical Solutions, comprising EPL Archives, MESM and Therapak.
- Sagard NewGen invests in Quipment, a leading player in clinical trial equipment solutions, to support its growth ambitions and accelerate international expansion (opens in a new tab)sagard.com
- Sagard's January 14, 2026 announcement describes a minority strategic investment in Quipment alongside its founders and management, intended to support growth and international expansion.
- Resonant Clinical Solutions Expands Global Equipment & Ancillaries Business with Acquisition of Labfish (opens in a new tab)resonantclinical.com
- On September 30, 2026, Resonant announced that it had acquired Germany-based Labfish and its United States and United Kingdom affiliates, adding rental equipment, calibration, kitting and import/export-related capabilities.
- Resonant Clinical Solutions and Haier Biomedical Introduce an Innovative Benchtop Centrifuge with a Natural Refrigerant (opens in a new tab)resonantclinical.com
- On October 7, 2026, Resonant and Haier Biomedical announced the launch of a natural-refrigerant benchtop centrifuge through an exclusive partnership.
AI in ancillary information work: promise exceeds adoption evidence
The clearest market-specific AI record found is historical. On April 8, 2020, Ancillare announced a communications platform combining ancillary-supply data with AI, analytics and collaboration. Planned functions included inventory alerts, shipment tracking and forecasting, with the first client version promised in the following weeks. This establishes a published offering and rollout intention—not current deployment scale, sustained customer adoption or demonstrated savings.
Digitization is more directly visible in marketed administrative tools. Quipment describes Quipsite as a platform for deployments, returns, resupplies, calibration records and budgets. Its inspected product page does not characterize those functions as AI, so they should not be relabelled as such.
The plausible cumulative business impact is better coordination of information, with AI potentially assisting document review, service-request routing and commercial exception identification. These are analytical possibilities, not established market-wide benefits. Investment decisions should depend on functioning capabilities, accountable human review and observable commercial results rather than broad claims about AI in clinical research.
Sources and supporting claims 2
- Ancillare Launches Digital Communications Platform (opens in a new tab)ancillare.com
- Ancillare's April 8, 2020 announcement described an AI-, analytics- and collaboration-enabled communications platform with planned inventory alerts, shipment tracking and forecasting; its first client version was promised in the following weeks.
- Quipsite Platform (opens in a new tab)quipment.com
- Quipment markets Quipsite for equipment deployments, returns, resupplies, closures, calibration records and budgets; the inspected product page does not characterize these functions as AI.
Regional service networks and trial-equipment access
North America. Quipment and Woodley publish United States service locations. FDA's September 2024 guidance also recognizes decentralized trial elements outside traditional sites. Together, these records support evaluating both site-equipment support and participant-facing fulfillment, without establishing the scale of either purchasing pattern.
Latin America. Ancillare's disclosed Brazilian depots provide evidence of an ancillary distribution channel. The commercial question is whether a provider can contract for the particular countries and services required—not whether one regional location proves uniform coverage. Regional inventory sufficiency and comparable service performance were not established.
Europe. Quipment's French technical service center and Woodley's United Kingdom presence show distinct service nodes. Buyers can consider regional support arrangements, but should distinguish a service location from equipment manufacturing and from guaranteed supply to other European destinations.
Middle East. Ancillare lists a Tel Aviv depot, while the GCC Health Council documents a separate public procurement channel for devices and supplies. Neither establishes comprehensive regional trial-equipment coverage. Sponsor procurement and public-health tender opportunities require separate commercial assessment.
Africa. Ancillare lists a South Africa depot. This supports the existence of a disclosed channel, not continent-wide stock or replacement capability. Country-specific service commitments beyond that disclosed node remain an evidence gap, rather than grounds to characterize other markets as inactive.
Asia-Pacific. Quipment's Japanese technical service center provides concrete evidence of regional support infrastructure. It does not establish equivalent access elsewhere in Asia-Pacific. The relevant comparison is the contracted combination of local support and cross-border delivery, not a supplier's headquarters location.
Sources and supporting claims 5
- Clinical Trial equipment supplier & rental | Woodley Trial Solutions (opens in a new tab)woodleytrialsolutions.com
- Woodley publishes United States service contact information, supporting the observation of a North American service presence.
- Global Deployment of Clinical Trials Equipment Solutions (opens in a new tab)quipment.com
- Quipment identifies technical service centers in France, the United States and Japan.
- Conducting Clinical Trials With Decentralized Elements (opens in a new tab)fda.gov
- FDA's September 2024 final guidance recognizes decentralized trial elements, including activities outside traditional trial sites.
- Why Ancillare (opens in a new tab)ancillare.com
- Ancillare lists Brazilian depots, a Tel Aviv depot and a South Africa depot, providing evidence of disclosed channels rather than region-wide inventory.
- الشراء الموحد (opens in a new tab)ghc.sa
- The GCC Health Council record establishes a broader public-health procurement channel, not clinical-trial equipment expenditure.
How geographic groupings affect trial-equipment access
ASEAN. The ASEAN Medical Device Directive establishes a harmonized framework but retains national registration and licensing responsibilities, including exemptions. Singapore's Health Sciences Authority separately describes national registration and dealer licensing. The commercial implication is coordinated regional planning with country-specific access checks—not an assumed ASEAN-wide permission for every rented device.
BRICS. An accessible PAHO account of the June 17, 2025 health meeting describes research cooperation and voluntary regulatory convergence. This is policy direction, not evidence of a common equipment authorization or pooled clinical-trial purchasing system. Implementation across BRICS was not established, so supplier access and counterparty responsibilities remain country-level questions.
European Union. CTIS provides a common application channel for multinational medicinal trials, with the transition for continuing trials ending on January 31, 2025. Shared administration can support coordinated supplier planning, but it does not create a single equipment buyer. The inspected trial-administration record does not establish device-specific market access or ancillary orders.
G7. The June 4, 2021 Therapeutics and Vaccines Clinical Trials Charter supports international trial coordination and research infrastructure. It is a cooperation commitment, not an equipment purchase. Commercial investment should therefore follow identifiable sponsor programs and contracts rather than attributing purchasing demand to the charter itself.
GCC. The GCC Health Council's joint-procurement program covers medical devices and supplies for participating public-health entities. This is a tangible procurement channel, but participation and tender scope matter. No trial-specific equipment award was established in this review, and public-health purchasing should not be conflated with pharmaceutical-sponsor procurement.
NATO. NATO's procurement portal makes eligibility and evaluation dependent on individual procurement calls. No NATO-specific clinical-trial equipment award was identified. The grouping is therefore relevant only where a documented opportunity expressly covers this market; broader defense procurement is not evidence of clinical-trial demand.
Sources and supporting claims 7
- ASEAN Medical Device Directive (opens in a new tab)asean.org
- The ASEAN Medical Device Directive provides for national registration, exemptions and licensing of persons responsible for placing devices on a member state's market.
- Medical devices (opens in a new tab)hsa.gov.sg
- Singapore's Health Sciences Authority describes national medical-device registration and dealer licensing for import and wholesale activities.
- Clinical Trials Regulation (opens in a new tab)ema.europa.eu
- The accessible EMA record describes CTIS as a single application platform for multinational medicinal trials and identifies January 31, 2025 as the end of the transition for continuing trials.
- Strengthening cooperation and exchange with BRICS countries key to advance priority health commitments, PAHO Director says (opens in a new tab)paho.org
- PAHO's account of the June 17, 2025 BRICS health meeting describes health-research cooperation and voluntary regulatory convergence, rather than an implemented common equipment-purchasing system.
- G7 Therapeutics and Vaccines Clinical Trials Charter (opens in a new tab)gov.uk
- The G7 charter published June 4, 2021 sets commitments for international trial coordination, regulatory cooperation and research infrastructure; it does not establish an equipment order.
- الشراء الموحد (opens in a new tab)ghc.sa
- The GCC Health Council describes joint procurement covering medical devices and supplies for member states and participating entities, including tender coordination with health ministries and hospitals.
- Procurement Opportunities (opens in a new tab)nato.int
- NATO's procurement portal states that eligibility requirements are specified in individual procurement documentation and that bids are evaluated by the procuring body.
Featured-country access to equipment and ancillary services
North America—United States, Canada and Mexico. The United States has published Quipment technical-service and Woodley service locations. FDA's decentralized-trial guidance adds context for participant-facing supply needs, but does not establish device purchases. Ancillare lists depots in Ontario, Canada, and Mexico City, Mexico. These records support identifiable channels; local inventory and calibration scope in Canada and Mexico were not established.
Latin America—Brazil. Ancillare lists depots in Rio de Janeiro and Brasilia. ANVISA's April 2024 communication distinguishes devices supporting medicinal trials from devices that are themselves under investigation. That historical distinction makes the declared commercial purpose relevant to supply planning, but the page is not confirmation of today's filing route or a particular supplier's import eligibility.
Europe—France, Germany and United Kingdom. France has a disclosed Quipment technical service center. Germany has Labfish's Hamburg-based rental and calibration business, acquired by Resonant in September 2026. The United Kingdom has Woodley's published service location. These are different forms of commercial presence and should not be treated as interchangeable evidence of inventory or manufacturing.
Europe—Italy, Spain and Russia. Italy's AIFA and Spain's AEMPS document the move to CTIS at the end of January 2025. Shared study administration offers a basis for coordinating supplier planning, but neither record establishes local equipment stock or ancillary contracts. For Russia, the inspected Roszdravnadzor page describes import notification for devices entering for state-registration purposes. It does not establish an available ancillary rental channel; current supplier commitments and equipment-specific access remain unresolved.
Asia-Pacific—Australia, India, China and South Korea. Ancillare identifies depots in Melbourne, Australia; India; Chengdu, China; and Seoul, South Korea. These disclosures provide prospective channel locations for buyer discussions. For each country, depot ownership, available models and replacement turnaround remain unconfirmed; the listings are not evidence of national device authorization.
Asia-Pacific—Japan. Quipment publishes a Japanese technical-service-center address, providing more specific evidence of a service function than a general global-delivery claim. The inspected record nevertheless does not disclose country-level sales, immediately available inventory or commercial response commitments.
Sources and supporting claims 9
- Clinical Trial equipment supplier & rental | Woodley Trial Solutions (opens in a new tab)woodleytrialsolutions.com
- Woodley publishes United Kingdom and United States locations.
- Global Deployment of Clinical Trials Equipment Solutions (opens in a new tab)quipment.com
- Quipment publishes French headquarters and technical-service addresses, a United States technical-service address and a Japanese technical-service address.
- Resonant Clinical Solutions Expands Global Equipment & Ancillaries Business with Acquisition of Labfish (opens in a new tab)resonantclinical.com
- The acquisition announcement identifies Labfish as a Hamburg-based provider of rental equipment and calibration services.
- Conducting Clinical Trials With Decentralized Elements (opens in a new tab)fda.gov
- The United States guidance addresses decentralized trial arrangements; it does not establish purchases of participant devices or equipment.
- Why Ancillare (opens in a new tab)ancillare.com
- Ancillare lists depots in Ontario, Canada; Mexico City, Mexico; Rio de Janeiro and Brasilia, Brazil; Melbourne, Australia; India; Chengdu, China; and Seoul, South Korea.
- Saiba quais são os códigos de importação de produtos para pesquisa clínica ou tecnológica (opens in a new tab)gov.br
- ANVISA's April 11, 2024 communication distinguishes medical devices supporting medicinal clinical research from devices that are themselves under clinical investigation.
- Osservatorio Nazionale sulla Sperimentazione Clinica dei Medicinali (OsSC): disposizioni a partire dal 31 gennaio 2025 (opens in a new tab)aifa.gov.it
- AIFA's notice addresses the end-January 2025 CTIS transition for ongoing Italian medicinal trials and the closure of the former channel for new substantial-amendment requests.
- Information on CTIS and Clinical Trials Regulation (EU) 536/2014 (opens in a new tab)aemps.gob.es
- AEMPS states that ongoing trials must operate under the Clinical Trials Regulation with authorization in CTIS from January 31, 2025.
- Федеральная служба по надзору в сфере здравоохранения (opens in a new tab)roszdravnadzor.gov.ru
- Roszdravnadzor's inspected page describes notification for importing medical devices for state-registration purposes; that scope does not establish an available clinical-trial ancillary rental channel.
Commercial choices for trial-equipment leaders
Compare purchasing models before consolidating vendors. Request separate commercial alternatives for rental, direct purchase and management of sponsor-owned assets. Compare extension charges, logistics, replacement commitments, return obligations and residual ownership. Rental is a candidate when duration or site demand is uncertain; ownership may be preferable when sustained reuse justifies the associated responsibilities. The choice should change when contracted utilization or extension economics change.
Expand service coverage against committed demand, not footprint claims alone. A partner-depot model offers an alternative to investing in an owned center. Before choosing, establish the counterparty's public commercial status, country responsibilities, available service scope and contractual response commitments. An owned-center investment becomes more defensible when repeat contracted demand and service economics support it; a location on a map is insufficient.
Requalify the commercial relationship after acquisitions. Confirm contracting entities, asset ownership, service boundaries and escalation responsibilities. Bundling equipment and ancillaries can reduce coordination work, but creates concentration risk. Retain a qualified alternative where continuity matters, and increase consolidation only when the combined provider demonstrates the required coverage under enforceable terms.
Buy digital visibility before assuming an AI premium is warranted. Existing portal functions offer a comparison point for AI-enabled information work. Consider AI for administrative exceptions or customer-service routing only where data rights, human accountability and measurable business benefits are clear. Use order-response time, correction rates and service exceptions as commercial indicators. Defer broader investment if the provider cannot distinguish functioning capabilities from announced features.
Sources and supporting claims 2
- Clinical Trial Ancillary Equipment Sourcing, Delivery & Recovery (opens in a new tab)resonantclinical.com
- Resonant's published rental, purchase and asset-management alternatives provide the commercial models considered in the purchasing recommendations; the source does not establish which is economically preferable.
- Quipsite Platform (opens in a new tab)quipment.com
- Quipsite's published administrative functions provide a non-AI-labelled alternative against which proposed AI investments can be compared.
Clinical-trial equipment research approach and evidence limits
This qualitative review uses a research cutoff of October 26, 2026. Research compared official supplier portfolios, published service locations, acquisition and investment announcements, regulator communications and intergovernmental procurement or policy records. Sources span the ASEAN device framework, the historical AI-platform announcement, the G7 charter and more recent commercial events. Native-language records were inspected where relevant, including Brazilian, Italian, Russian and GCC material.
The analysis separated rental, direct purchase, asset management, services and consumable supply. It also distinguished completed acquisitions from investment ambitions, product launches from local availability, and medicinal-trial administration from equipment market access. Some official pages were only partially retrievable; narrow conclusions rely on their accessible returned text rather than an assertion of complete document review.
No interviews, surveys, transaction-price analysis or quantitative market modelling were performed. Supplier disclosures establish advertised capabilities, not independently audited performance. Country sales, immediately available inventory, depot ownership, contract economics and widespread current AI adoption remain incompletely evidenced. Geographic group identities were not treated as evidence of current membership or uniform implementation.
Trial-equipment competition will turn on demonstrated service delivery
The inspected record shows a market competing through combinations of equipment access, ancillary supply and lifecycle services. Ownership changes, Quipment's expansion investment and the Resonant–Haier product partnership provide concrete evidence of strategic activity. They do not establish broad-based purchasing growth or commercial success.
The most useful milestones are demonstrated delivery commitments rather than announcements alone: evidence of Labfish integration, disclosed country-level service expansion following investment, and local commercial availability of newly launched offerings. For AI, active capabilities and attributable administrative benefits matter more than a historical platform announcement.
The central commercial proposition is credible: buyers can obtain equipment and support through several ownership and service models. The unresolved question is which provider can deliver the required country coverage and contract economics for a particular study. This review establishes offerings and selected access conditions, but not comparable country sales, available stock or market-wide adoption.
Sources and supporting claims 3
- Sagard NewGen invests in Quipment, a leading player in clinical trial equipment solutions, to support its growth ambitions and accelerate international expansion (opens in a new tab)sagard.com
- The announced purpose of Sagard's investment was expansion; the announcement alone does not establish subsequent country-level service expansion.
- Resonant Clinical Solutions Expands Global Equipment & Ancillaries Business with Acquisition of Labfish (opens in a new tab)resonantclinical.com
- The announced acquisition broadens Resonant's equipment-and-ancillaries capabilities; it does not report completed integration outcomes.
- Resonant Clinical Solutions and Haier Biomedical Introduce an Innovative Benchtop Centrifuge with a Natural Refrigerant (opens in a new tab)resonantclinical.com
- The announcement establishes a product launch and exclusive partnership, not universal country availability or demonstrated commercial adoption.
Research report
Table of contents
- 1.Preface
- 1.1Objectives of the Study
- 1.2Market Definition
- 1.3Market Segmentation & Coverage
- 1.4Years Considered for the Study
- 1.5Currency Considered for the Study
- 1.6Language Considered for the Study
- 1.7Key Stakeholders
- 2.Research Methodology
- 2.1Introduction
- 2.2Research Design
- 2.2.1Primary Research
- 2.2.2Secondary Research
- 2.3Research Framework
- 2.3.1Qualitative Analysis
- 2.3.2Quantitative Analysis
- 2.4Market Size Estimation
- 2.4.1Top-Down Approach
- 2.4.2Bottom-Up Approach
- 2.5Data Triangulation
- 2.6Research Outcomes
- 2.7Research Assumptions
- 2.8Research Limitations
- 3.Executive Summary
- 3.1Introduction
- 3.2CXO Perspective
- 3.3New Revenue Opportunities
- 3.4Next-Generation Business Models
- 3.5Industry Roadmap
- 4.Market Overview
- 4.1Introduction
- 4.2Key Growth Contribution
- 4.3Industry Ecosystem & Value Chain Analysis
- 4.3.1Supply-Side Analysis
- 4.3.2Demand-Side Analysis
- 4.3.3Stakeholder Analysis
- 4.4Market Dynamics
- 4.4.1Key Drivers
- 4.4.2Key Restraints
- 4.4.3Key Opportunities
- 4.4.4Key Challenges
- 4.5Porter’s Five Forces Analysis
- 4.6PESTLE Analysis
- 4.7Market Outlook
- 4.7.1Near-Term Market Outlook (0-2 Years)
- 4.7.2Medium-Term Market Outlook (3-5 Years)
- 4.7.3Long-Term Market Outlook (5-10 Years)
- 4.8Go-to-Market Strategy
- 5.Market Insights
- 5.1Consumer Insights & End-User Perspective
- 5.2Consumer Experience Benchmarking
- 5.3Opportunity Mapping
- 5.4Distribution Channel Analysis
- 5.5Pricing Trend Analysis
- 5.6Regulatory Compliance & Standards Framework
- 5.7ESG & Sustainability Analysis
- 5.8Disruption & Risk Scenarios
- 5.9Return on Investment & Cost-Benefit Analysis
- 6.Cumulative Impact of Artificial Intelligence 2026
- 7.Clinical Trial Equipment & Ancillary Solutions Market, by Region
- 7.1Introduction
- 7.2Asia-Pacific
- 7.3North America
- 7.4Latin America
- 7.5Europe
- 7.6Middle East
- 7.7Africa
- 8.Clinical Trial Equipment & Ancillary Solutions Market, by Group
- 8.1Introduction
- 8.2ASEAN
- 8.3GCC
- 8.4European Union
- 8.5BRICS
- 8.6G7
- 8.7NATO
- 9.Clinical Trial Equipment & Ancillary Solutions Market, by Country
- 9.1Introduction
- 9.2United States
- 9.3Canada
- 9.4Mexico
- 9.5Brazil
- 9.6United Kingdom
- 9.7Germany
- 9.8France
- 9.9Russia
- 9.10Italy
- 9.11Spain
- 9.12China
- 9.13India
- 9.14Japan
- 9.15Australia
- 9.16South Korea
- 10.Competitive Landscape
- 10.1Market Share Analysis, 2025
- 10.2Market Concentration Analysis, 2025
- 10.3Recent Developments & Impact Analysis, 2025
- 10.4Product Portfolio Analysis, 2025
- 10.5Benchmarking Analysis, 2025
- 11.Key Experts